Skip to main content

Becton Dickinson company profile

  • BDX · NYSE
  • Medical devices
  • Health Care Equipment
  • S&P 500
$218.03+1.08%Close 13 Nov 2026 · Market value $59.20B

About Becton Dickinson

Becton, Dickinson and Company (BD) is a global medical technology company that develops, manufactures and sells medical supplies, devices, laboratory equipment and diagnostic products. Its customers include healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical companies and the general public. Its product lines span medication management and infusion systems, prefillable drug delivery systems, advanced patient monitoring, specimen collection, infectious disease diagnostics, cell analysis reagents and instruments, and vascular, urology and surgical specialty products. BD manufactures and sells its products worldwide, with manufacturing operations in 18 countries outside the United States and sales organized across EMEA, Greater Asia, Latin America and Canada, in addition to the United States.

A summary of the business section of the company's latest annual report, filed 25 Nov 2025.

Company facts

TickerBDX · NYSE
SectorMedical devices
IndustryHealth Care Equipment
IndexS&P 500
Fiscal year ends30 September
Reporting currencyUSD
CIK10795
Latest annual report10-K, filed 25 Nov 2025

Officers and directors

NameRoleShares ownedLatest Form 4
Thomas E. PolenChairman, CEO and President · Director528K · < 1%Disposition to the issuer, 13 Aug 2026
Michael D. GarrisonEVP & Pres Med.Essntl&BioPharm87.6K · < 1%Sale under a 10b5-1 plan, 24 Jun 2026
Richard E. ByrdEVP & President Interventional83.1K · < 1%Shares withheld for tax, 26 Nov 2025
Christopher J. DelOreficeEVP & Chief Financial Officer65.7K · < 1%Shares withheld for tax, 26 Nov 2025
Timothy M. RingDirector60.1K · < 1%Grant or award, 27 Jan 2026
Bertram L. ScottDirector54.2K · < 1%Open-market sale, 18 Feb 2026
Christopher JonesDirector34.2K · < 1%Grant or award, 27 Jan 2026
Claire M. Fraser, Ph.D.Director22.6K · < 1%Open-market sale, 10 Sep 2025
Catherine M. BurzikDirector14.9K · < 1%Grant or award, 28 Jan 2025
R. Andrew EckertDirector9.3K · < 1%Grant or award, 27 Jan 2026
Jeffrey W. HendersonDirector8.0K · < 1%Grant or award, 27 Jan 2026
Gregory J. HayesDirector6.1K · < 1%Grant or award, 27 Jan 2026
Carrie L. Byington, M.D.Director5.5K · < 1%Grant or award, 27 Jan 2026
Michael C. FeldEVP, Chief Revenue Officer4.1K · < 1%Sale under a 10b5-1 plan, 28 Sep 2026
William M. BrownDirector3.5K · < 1%Grant or award, 27 Jan 2026
Joanne Waldstreicher, M.D.Director2.3K · < 1%Grant or award, 27 Jan 2026
Robert L. HuffinesDirector180 · < 1%Grant or award, 27 Jan 2026
Jacqueline WrightDirector180 · < 1%Grant or award, 27 Jan 2026
Roque VitorEVP & Chief Financial Officer—Shares withheld for tax, 2 Sep 2026
Goette RolandEVP and President, EMEA—Open-market sale, 11 Aug 2026

Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.

BDX in the terminal

The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.